Hikma Has An Appetite For More Deals As It Builds On Acquisitions
CEO Siggi Olafsson Discusses Future Deal Targets, Including In Biosimilars
Hikma has the financial firepower and appetite to maintain its current deal-making momentum following several key transactions over the past year, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview, while also detailing how the firm plans to build up its US biosimilars business.
